Anti-AXL therapeutic antibody (Pre-made Enapotamab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Enapotamab vedotin (HuMax®-AXL-ADC) is an antibody-drug conjugate (ADC) targeted to Axl (from anexelekto, or uncontrolled growth). Axl is a unique RTK that is aberrantly expressed in many solid tumor types and is implicated in tumor cell proliferation, migration, and invasion.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-179-1mg	1mg	Inquiry
GMP-Bios-ab-179-10mg	10mg	Inquiry
GMP-Bios-ab-179-100mg	100mg	Inquiry
GMP-Bios-ab-179-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-AXL therapeutic antibody (Pre-made Enapotamab biosimilar,Whole mAb ADC)
INN Name	Enapotamab
Target	AXL
Format	Whole mAb ADC
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Genmab
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	na